A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond : Episode 3

Video

March 23, 2023

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

Author(s):

Kathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

EP: 1.Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP: 2.Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

Now Viewing

EP: 3.Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP: 4.Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP: 5.Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP: 6.Treatment Approaches for Patients with RCC and Bone Metastases

EP: 7.Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP: 8.Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP: 9.Updates in the Adjuvant Treatment of Metastatic RCC

EP: 10.Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

EP: 11.Preferred Treatment Regimens for Refractory RCC

EP: 12.Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP: 13.Genetic Counseling for Patients with Non-Clear Cell RCC

Related Content

December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com

November 27th 2024

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sandy Srinivas, MD, of Stanford Medicine

November 21st 2024

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

November 9th 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC